FR24C1011I2 - Diaminopyrimidines utilisees en tant qu'antagonistes de p2x3 et p2x2/3 - Google Patents

Diaminopyrimidines utilisees en tant qu'antagonistes de p2x3 et p2x2/3

Info

Publication number
FR24C1011I2
FR24C1011I2 FR24C1011C FR24C1011C FR24C1011I2 FR 24C1011 I2 FR24C1011 I2 FR 24C1011I2 FR 24C1011 C FR24C1011 C FR 24C1011C FR 24C1011 C FR24C1011 C FR 24C1011C FR 24C1011 I2 FR24C1011 I2 FR 24C1011I2
Authority
FR
France
Prior art keywords
diaminopyrimidines
antagonists
diaminopyrimidines used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1011C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of FR24C1011I1 publication Critical patent/FR24C1011I1/fr
Application granted granted Critical
Publication of FR24C1011I2 publication Critical patent/FR24C1011I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR24C1011C 2004-03-05 2024-03-12 Diaminopyrimidines utilisees en tant qu'antagonistes de p2x3 et p2x2/3 Active FR24C1011I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55049904P 2004-03-05 2004-03-05
PCT/EP2005/002020 WO2005095359A1 (fr) 2004-03-05 2005-02-25 Diaminopyrimidines utilisees en tant qu'antagonistes de p2x3 et p2x2/3

Publications (2)

Publication Number Publication Date
FR24C1011I1 FR24C1011I1 (fr) 2024-05-24
FR24C1011I2 true FR24C1011I2 (fr) 2024-12-13

Family

ID=34961010

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1011C Active FR24C1011I2 (fr) 2004-03-05 2024-03-12 Diaminopyrimidines utilisees en tant qu'antagonistes de p2x3 et p2x2/3

Country Status (31)

Country Link
US (12) US7858632B2 (fr)
EP (2) EP2343282B1 (fr)
JP (4) JP4717876B2 (fr)
KR (1) KR100822530B1 (fr)
CN (1) CN1930135B (fr)
AR (1) AR047992A1 (fr)
AU (1) AU2005229331B2 (fr)
BE (1) BE2024C508I2 (fr)
BR (2) BR122018003623B8 (fr)
CA (1) CA2557372C (fr)
CY (2) CY1113450T1 (fr)
DK (1) DK1725540T5 (fr)
ES (2) ES2391636T3 (fr)
FI (1) FIC20240007I1 (fr)
FR (1) FR24C1011I2 (fr)
HR (1) HRP20120901T1 (fr)
HU (1) HUS2400005I1 (fr)
IL (2) IL177438A (fr)
LT (1) LTC1725540I2 (fr)
LU (1) LUC00333I2 (fr)
MY (1) MY145465A (fr)
NL (1) NL301261I2 (fr)
NO (4) NO339497B1 (fr)
NZ (1) NZ549069A (fr)
PL (1) PL1725540T3 (fr)
PT (1) PT1725540E (fr)
RU (1) RU2422441C2 (fr)
SI (1) SI1725540T1 (fr)
TW (1) TWI313604B (fr)
WO (1) WO2005095359A1 (fr)
ZA (1) ZA200606880B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2391636T3 (es) * 2004-03-05 2012-11-28 F. Hoffmann-La Roche Ag Diaminopirimidinas como antagonistas de P2X3 y P2X2/3
US8592419B2 (en) * 2004-10-29 2013-11-26 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
WO2007025901A1 (fr) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines comme modulateurs p2x3 et p2x2/3
CN101253158B (zh) * 2005-09-01 2013-07-10 弗·哈夫曼-拉罗切有限公司 合成芳氧基二氨基嘧啶类化合物的方法
KR101012926B1 (ko) * 2005-09-01 2011-02-09 에프. 호프만-라 로슈 아게 Ｐ2ｘ3 및 ｐ2ｘ2/3 조정자로서의 다이아미노피리미딘
JP4850912B2 (ja) * 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ３ｘ２／３モジュレーターとしてのジアミノピリミジン
ES2612890T3 (es) * 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
EP1770089A1 (fr) * 2005-10-03 2007-04-04 Institut Pasteur Dérivés de pyranodibenzofurannes ayant une activité antifongique et antibactérienne
JP5128603B2 (ja) 2006-10-04 2013-01-23 エフ．ホフマン−ラ ロシュ アーゲー フェノキシジアミノピリミジン誘導体の合成方法
AU2007316681B2 (en) * 2006-11-09 2013-01-24 F. Hoffmann-La Roche Ag Thiazole and oxazole-substituted arylamides
WO2008104472A1 (fr) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Dérivés de 2, 4 -diaminopyrimidine et utilisation de ces derniers comme antagonistes p2x ou comme promédicaments de ceux-ci
WO2008104474A1 (fr) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
CN101679246A (zh) 2007-03-30 2010-03-24 盐野义制药株式会社 新型吡咯啉酮衍生物以及包含其的药物组合物
EP2674417A3 (fr) * 2007-11-21 2014-04-09 Decode Genetics EHF Inhibiteurs de pde4 biaryle pour le traitement de l'inflammation
TW201016702A (en) * 2008-09-25 2010-05-01 Shionogi & Co Novel pyrrolinone derivative and pharmaceutical composition comprising the same
RU2011117722A (ru) 2008-11-06 2012-12-20 Фонд Медицинского Университета Южной Каролины по развитию научных исследований Лизосомотропные ингибиторы кислой церамидазы
KR101239571B1 (ko) 2008-11-24 2013-03-06 바스프 에스이 열잠재성 염기를 포함하는 경화성 조성물
US20120035268A1 (en) * 2008-12-30 2012-02-09 Szulc Zdzislaw M Sphingo-guanidines and their use as inhibitors of sphingosine kinase
CN102395571B (zh) 2009-02-13 2015-12-16 盐野义制药株式会社 三嗪衍生物及含有该三嗪衍生物的药物组合物
NZ598262A (en) 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
US9212130B2 (en) 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
PL2604595T3 (pl) 2010-08-10 2016-09-30 Pochodna triazyny i związek farmaceutyczny, który ją zawiera i wykazuje aktywność przeciwbólową
US9550763B2 (en) 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
CR20160093A (es) 2013-08-23 2016-08-26 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub aguda o cronica
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US10195198B2 (en) 2014-07-03 2019-02-05 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
AU2015313221B2 (en) 2014-09-09 2019-11-21 Cytokinetics Incorporated Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
RU2585727C1 (ru) * 2014-12-12 2016-06-10 Наталья Борисовна Гусева Способ лечения детей с гиперактивным мочевым пузырем
PT3355889T (pt) 2015-09-29 2023-04-26 Afferent Pharmaceuticals Inc Moduladores de recetores de diaminopirimidina p2x3 e p2x2/3 para utilização no tratamento da tosse
WO2017160569A1 (fr) 2016-03-14 2017-09-21 Afferent Pharmaceuticals Inc. Pyrimidines et variantes de celles-ci, et leurs utilisations
CA3018180C (fr) 2016-03-25 2024-02-20 Ronald Charles Hawley Pyrimidines et variants de celles-ci, et leurs utilisations
CN106083653A (zh) * 2016-06-06 2016-11-09 江苏天和制药有限公司 奥美普林中间体肉桂腈的合成方法
US10676444B2 (en) 2016-12-20 2020-06-09 Afferent Pharmaceuticals, Inc. Crystalline salts and polymorphs of a P2X3 antagonist
ES2980935T3 (es) * 2017-11-01 2024-10-03 Beijing Tide Pharmaceutical Co Ltd Antagonista del receptor p2x3 y/o p2x2/3, composición farmacéutica que lo comprende y su uso
AU2019257606B2 (en) * 2018-04-23 2025-01-30 Msd Werthenstein Biopharma Gmbh Novel process for synthesis of a phenoxy diaminopyrimidine compound
CN112262121A (zh) * 2018-06-15 2021-01-22 法尔玛赞公司 用于制备他喷他多的新方法
AU2020265969B2 (en) 2019-04-30 2025-10-02 Beijing Tide Pharmaceutical Co., Ltd. Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof
SG11202111877TA (en) * 2019-04-30 2021-11-29 Beijing Tide Pharmaceutical Co Ltd Method for treating cough by using diaminopyrimidine compound
BR112021021738A2 (pt) * 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3
MX2021014116A (es) 2019-05-31 2021-12-10 Chiesi Farm Spa Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
EP3981765A4 (fr) 2019-06-06 2023-05-31 Beijing Tide Pharmaceutical Co., Ltd. Antagoniste du récepteur p2x3 et/ou p2x2/3, composition pharmaceutique le contenant et son utilisation
CN110551147B (zh) * 2019-09-29 2021-11-26 蚌埠产品质量监督检验研究院 一种3-环丙基苯硼酸的合成方法
TWI849314B (zh) * 2020-06-01 2024-07-21 日商住友化學股份有限公司 化合物、樹脂、抗蝕劑組成物及抗蝕劑圖案的製造方法
JP2023536986A (ja) 2020-08-13 2023-08-30 上海拓界生物医薬科技有限公司 ベンズイミダゾール誘導体、その調製方法及び医薬用途
EP4214195A1 (fr) 2020-09-17 2023-07-26 Teva Pharmaceuticals International GmbH Formes à l'état solide de gefapixant et leur procédé de préparation

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2658897A (en) 1951-06-27 1953-11-10 Burroughs Wellcome Co 2, 4-diamino-5-benzyl pyrimidines
US2657206A (en) * 1951-07-30 1953-10-27 Burroughs Wellcome Co 2, 4-diamino-5-aryloxy-pyrimidines
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method
US2909522A (en) 1957-02-21 1959-10-20 Burroughs Wellcome Co Trialkoxybenzylpyrimidines and method
US3991050A (en) 1969-03-06 1976-11-09 Burroughs Wellcome Co. Preparation of β-Amino-α-benzylacrylonitriles
US3849470A (en) 1969-03-06 1974-11-19 Burroughs Wellcome Co 5-benzyl pyrimidines intermediates therefore,and method
US3850927A (en) 1969-03-06 1974-11-26 Burroughs Wellcome Co 5-benzyl pyrimidines intermediates therefore,and method
US3852276A (en) 1969-03-06 1974-12-03 Burroughs Wellcome Co 5-benzyl pyrimidines intermediate therefore, and method
GB1261455A (en) * 1969-03-06 1972-01-26 Burroughs Wellcome Co Improvements in or relating to substituted acrylonitriles
US4052553A (en) 1969-03-06 1977-10-04 Burroughs Wellcome Co. 5-benzyl pyrimidines intermediates therefore, and method
US3855265A (en) 1969-03-06 1974-12-17 Burroughs Wellcome Co 5-benzyl pyrimidines intermediates therefore, and method
US3878252A (en) * 1970-09-24 1975-04-15 Burroughs Wellcome Co Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide
BR6915082D0 (pt) * 1969-05-16 1973-03-08 Wellcome Found Processo de preparacao de benzil-pirimidinas
CH513181A (de) 1969-06-12 1971-09-30 Hoffmann La Roche Verfahren zur Herstellung von N-Oxyden von Benzylpyrimidinen
US4255574A (en) 1973-02-26 1981-03-10 Hoffmann-La Roche Inc. Process for preparing 2,4-diamino-pyrimidines
US4143227A (en) 1973-02-26 1979-03-06 Hoffmann-La Roche Inc. Process for substituted 5-benzyl-2,4-diamino-pyrimidines
US3931181A (en) 1973-07-27 1976-01-06 Hoffmann-La Roche Inc. 2,4-Diamino-5-benzylpyrimidines
US4515948A (en) 1973-09-12 1985-05-07 Hoffmann-La Roche Inc. 2,4-Diamino-5-(4-amino and 4-dimethylamino-3,5-dimethoxy benzyl)pyrimidines
CH591457A5 (fr) 1973-11-08 1977-09-15 Hoffmann La Roche
US3940393A (en) 1974-06-21 1976-02-24 American Home Products Corporation Synthesis of 2,6-diaminopyrimidines
US4039543A (en) 1974-12-24 1977-08-02 Hoffmann-La Roche Inc. Benzylpyrimidines
US4033962A (en) 1975-06-26 1977-07-05 Hoffman-La Roche Inc. 2,4-Diamino-pyrimidine derivatives and processes
GB1582245A (en) 1976-06-09 1981-01-07 Wellcome Found Benzyl cyanoacetal derivatives and their conversion to pyrimidine derivatives
US4115650A (en) 1976-11-17 1978-09-19 Hoffmann-La Roche Inc. Process for preparing 2,4-diamino-5-(substituted benzyl)-pyrimidines
US4075209A (en) 1977-02-07 1978-02-21 Hoffmann-La Roche, Inc. Process for preparing substituted 2,4-diaminopyrimidines and isoxazole intermediate
FR2397407A2 (fr) 1977-07-11 1979-02-09 Dick Pierre Derives de 2,4-diamino pyrimidines et leur mise en solution en association avec des sulfamides
US4258045A (en) 1979-11-30 1981-03-24 Merck & Co., Inc. Inhibitor of dihydrofolate reductase
DE3045720A1 (de) 1980-12-04 1982-07-08 Basf Ag, 6700 Ludwigshafen N-pyrimidinyl-carbaminsaeureester, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
FR2502152A1 (fr) 1981-03-20 1982-09-24 Panmedica Laboratoires Nouveaux derives solubles n2 substitues de la diamino-2,4-benzyl-5-pyrimidines, leur procede de preparation et medicaments les contenant
IT1138146B (it) 1981-08-11 1986-09-17 Proter Spa Processo per la produzione della 2,4-diammino-(3,5-dimetossi-4-metos sietossi-benzil)-pirimidina
GB2116962A (en) * 1982-03-18 1983-10-05 Ciba Geigy Ag Nitriles; pyrimidines
US4590271A (en) 1982-05-01 1986-05-20 Burroughs Wellcome Co. 2,4-diamino-5-(substituted)pyrimidines, useful as antimicrobials
US4587341A (en) 1982-05-07 1986-05-06 Burroughs Wellcome Co. 2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or unsubstituted)-6-quinolylmethyl)pyrimidines, useful as antimicrobials
US4515574A (en) * 1983-02-16 1985-05-07 The Zeller Corporation Universal joint seal with multiple lips
DE3603577A1 (de) 1986-02-06 1987-08-13 Joachim K Prof Dr Seydel Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit
FR2595697B1 (fr) * 1986-03-13 1988-07-08 Rousselot Cie Derives de benzyl-pyrimidine, leur procede de preparation ainsi que les compositions en contenant
HU199683B (en) 1987-07-22 1990-03-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions analgesic, antiphlogistic, antipyretic, antianginic and/or antioxidative activity
US4996198A (en) 1988-07-11 1991-02-26 Hoffmann-La Roche Inc. Anticoccidial composition
US5240640A (en) 1990-06-04 1993-08-31 Coulter Corporation In situ use of gelatin or an aminodextran in the preparation of uniform ferrite particles
US5258373A (en) 1991-07-17 1993-11-02 Hoffmann-La Roche Inc. Anticoccidial compositions
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
WO1996016963A1 (fr) 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamides et leur utilisation comme medicaments
CA2162630C (fr) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6136971A (en) 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6211185B1 (en) 1999-05-05 2001-04-03 Veterinary Pharmacy Corporation Concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution, and a suspending agent
ES2295048T3 (es) 1999-09-03 2008-04-16 Actelion Pharmaceuticals Ltd. Bis-sulfonamidas.
DE60025837T2 (de) 1999-09-24 2006-11-02 Janssen Pharmaceutica N.V. Antivirale feste dispersionen
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
US6515198B2 (en) * 2000-02-15 2003-02-04 Syntex (U.S.A.) Llc Use of purinergic receptor modulators and related reagents
AU2001263850A1 (en) 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
WO2001081338A1 (fr) 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Sulfonylaminopyrimidines substituees
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
NZ524172A (en) 2000-09-25 2004-09-24 Actelion Pharmaceuticals Ltd Arylalkane-sulfonamides useful as endothelin receptor antagonists
WO2002053557A1 (fr) 2000-12-18 2002-07-11 Actelion Pharmaceuticals Ltd Nouveaux sulfamides et leur utilisation comme antagonistes du recepteur de l'endotheline
US6423720B1 (en) 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same
WO2002083650A1 (fr) 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Nouvelles sulfonylamino-pyrimidines
EP1392643B1 (fr) * 2001-05-18 2005-09-14 Abbott Laboratories (1s)-1,2,3,4-tetrahydro-1-naphthalenyle] benzamides trisubstitues en n qui inhibent des recepteurs contenant des antagonistes p2x3 et p2x2/3
WO2003042190A1 (fr) * 2001-11-12 2003-05-22 Pfizer Products Inc. Derives de n-adamantylalkyle benzamide en tant qu'antagonistes du recepteur p2x7
ES2391636T3 (es) * 2004-03-05 2012-11-28 F. Hoffmann-La Roche Ag Diaminopirimidinas como antagonistas de P2X3 y P2X2/3
KR101012926B1 (ko) * 2005-09-01 2011-02-09 에프. 호프만-라 로슈 아게 Ｐ2ｘ3 및 ｐ2ｘ2/3 조정자로서의 다이아미노피리미딘
WO2007025901A1 (fr) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines comme modulateurs p2x3 et p2x2/3
JP4850912B2 (ja) * 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ３ｘ２／３モジュレーターとしてのジアミノピリミジン
WO2008104472A1 (fr) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Dérivés de 2, 4 -diaminopyrimidine et utilisation de ces derniers comme antagonistes p2x ou comme promédicaments de ceux-ci

Also Published As

Publication number Publication date
SI1725540T1 (sl) 2012-12-31
US20180141919A1 (en) 2018-05-24
CA2557372C (fr) 2013-01-08
JP2011252004A (ja) 2011-12-15
US20230100975A1 (en) 2023-03-30
US20240158356A1 (en) 2024-05-16
TWI313604B (en) 2009-08-21
HRP20120901T1 (hr) 2012-12-31
JP5465700B2 (ja) 2014-04-09
HUS2400005I1 (hu) 2024-04-28
US20190270713A1 (en) 2019-09-05
EP1725540A1 (fr) 2006-11-29
ES2391636T3 (es) 2012-11-28
US20170096404A1 (en) 2017-04-06
LTPA2024508I1 (fr) 2024-04-10
BRPI0508461B8 (pt) 2021-05-25
US9556127B2 (en) 2017-01-31
JP2011126899A (ja) 2011-06-30
NO20064065L (no) 2006-11-28
LUC00333I2 (fr) 2024-10-04
IL177438A (en) 2012-10-31
US20190016688A1 (en) 2019-01-17
HK1101074A1 (en) 2007-10-05
US8846705B2 (en) 2014-09-30
IL177438A0 (en) 2006-12-10
CN1930135A (zh) 2007-03-14
IL217453A0 (en) 2012-02-29
US20200115347A1 (en) 2020-04-16
PL1725540T3 (pl) 2013-02-28
JP2007526268A (ja) 2007-09-13
CY1113450T1 (el) 2016-06-22
US20250066309A1 (en) 2025-02-27
AU2005229331A1 (en) 2005-10-13
DK1725540T5 (da) 2012-10-22
BRPI0508461A (pt) 2007-07-31
ZA200606880B (en) 2008-04-30
US20050209260A1 (en) 2005-09-22
BR122018003623B8 (pt) 2021-07-27
US7858632B2 (en) 2010-12-28
RU2422441C2 (ru) 2011-06-27
AU2005229331B2 (en) 2011-10-13
BRPI0508461B1 (pt) 2018-05-15
BR122018003623B1 (pt) 2018-10-09
JP2014193906A (ja) 2014-10-09
US20210009531A1 (en) 2021-01-14
DK1725540T3 (da) 2012-10-01
CN1930135B (zh) 2011-12-28
KR100822530B1 (ko) 2008-04-16
CA2557372A1 (fr) 2005-10-13
KR20060117366A (ko) 2006-11-16
NZ549069A (en) 2010-09-30
JP5576314B2 (ja) 2014-08-20
MY145465A (en) 2012-02-15
NO339497B1 (no) 2016-12-19
JP4717876B2 (ja) 2011-07-06
NO20161635A1 (no) 2016-10-12
PT1725540E (pt) 2012-11-29
IL217453A (en) 2014-12-31
JP5886898B2 (ja) 2016-03-16
NL301261I2 (nl) 2024-03-25
EP2343282B1 (fr) 2015-07-22
LTC1725540I2 (fr) 2024-07-10
RU2006135203A (ru) 2008-04-10
US20110077242A1 (en) 2011-03-31
US20140357629A1 (en) 2014-12-04
CY2024006I2 (el) 2024-09-20
ES2548022T3 (es) 2015-10-13
FIC20240007I1 (fi) 2024-03-13
TW200539885A (en) 2005-12-16
NO20150504L (no) 2006-11-28
NO343755B1 (no) 2019-05-27
EP2343282A1 (fr) 2011-07-13
WO2005095359A1 (fr) 2005-10-13
FR24C1011I1 (fr) 2024-05-24
NO2024010I1 (no) 2024-03-06
AR047992A1 (es) 2006-03-15
BE2024C508I2 (fr) 2024-08-08
CY2024006I1 (el) 2024-09-20
EP1725540B1 (fr) 2012-09-12

Similar Documents

Publication Publication Date Title
FR24C1011I1 (fr) Diaminopyrimidines utilisees en tant qu'antagonistes de p2x3 et p2x2/3
DK1924264T3 (da) Diaminopyrimidiner som p2x3- og p2x2/3-modulatorer
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
DK1638969T3 (da) CGRP-receptorantagonister
UA95768C2 (ru) Антагонисты мускариновых рецепторов ацетилхолина
EP1871752A4 (fr) Antagonistes du récepteur de l' orexine de type amidopropoxyphényle
SMP200600024B (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
IL238702A (en) Tetraazole Arilamide History and their Use as Antagonists for P2x3 and / or P2x2 / 3 Porinergic Receptors
ITUD20050152A1 (it) Dispositivo elettro-ottico per il conteggio di persone,od altro,basato su visione stereoscopica,e relativo procedimento
EP1878809A4 (fr) MATERIAU DE CABLAGE EN ALLIAGE Al-Ni-B ET STRUCTURE D ELEMENT L'UTILISANT
DK1893603T3 (da) Piperidin-4-YL-amidderivater og anvendelsen deraf som SST-receptorundertype 5-antagonister
FR2884826B1 (fr) Composition de polissage et procede de polissage l'utilisant
EP1870368A4 (fr) Dispositif d'ascenseur
EP1878745A4 (fr) Récepteur de l'humanine ou récepteur du polypeptide de type humanine
TH0501000934B (th) ไดอะมิโนไพริมิดีน (Diaminopyrimidines) ต่างๆ ที่เป็นแอนทาโกนิสท์ของ P2X3 และ P2X2/3
FR2866666B1 (fr) About d'echafaudage
FI20031228L (fi) Sihtirakenne käytettäväksi kuitutuotteen valmistuksessa
EP1882667A4 (fr) Dispositif d'ascenseur
ITUD20040046A1 (it) Dispositivo per l'illuminazione di facciate di edifici
ITRA20050027A1 (it) Stopper brooch "stappali & spillali"
EP1930283A4 (fr) Dispositif d'ascenseur
UA12046S (uk) Медаль учасника виставки
ITRM20040388A1 (it) Pipino l'appaiacalzino
ITTR20050007U1 (it) "progetto vergine"
ITBO20050127A1 (it) Dispositivo per la deformazione di porzioni inferiori di pantaloni o simili